In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.
Please enable it in your browser's preferences.
You can visit our support center if you're having problems.
We recommend upgrading to the latest
Please check your internet connection and refresh the page. You might also try disabling any ad blockers.